The LDA has a long history of funding/supporting research projects that lead to real results. Below is the list of links to peer-reviewed articles that acknowledge LDA’s funding/support. Click on the publication link (or just scroll down to it) to see the authors, which authors LDA provided the funding for (green), and the abstract and […]
LDA strives to fund the most relevant and cutting edge research aimed at investigating the diagnosis, treatment, pathology, and prevention of Lyme and other tick-borne diseases. The goal is to have researchers publish in peer review and move the field of tick-borne diseases forward. To date, LDA has 54 publications that have resulted from its […]
Does Bartonella Contribute to the Occurrence of Cutaneous Lesions and Neuropsychiatric Symptoms in Patients?
Results of the study, “Bartonella Associated Cutaneous Lesions (BACL) in People with Neuropsychiatric Symptoms” was recently published in the journal, Pathogens, as part of the special issue, “The Evolving Biomedical Importance of Bartonella Species Infections.” The study’s authors describe Bartonella spp. test results for participants who reported neuropsychiatric symptoms, with a majority reporting the concurrent incidence of cutaneous lesions.
The CDC published, in the February edition of its “Emerging Infectious Diseases,” two new papers pertaining to Lyme disease case numbers. CDC indicates that the researchers found ~ 476,000 people are diagnosed with and treated for Lyme disease each year in the U.S. This is a 59% increase from their previous estimate of ~300,000. Also, CDC posted a new page to its website, Syndromic Surveillance of Emergency Department Visits for Tick Bites, showing tick bites by time, age/sex, and region.
Virulence of Borrelia involves multiple channels for transmission and establishment in multiple tissues, as well as evasion of the host immune responses. The bacteria undergo significant changes in gene expression and multiply and spread once transmitted to the host. These changes induce inflammatory responses that, in humans, result in clinical signs and symptoms of disease. In […]
On Thursday, December 17, 2020, Project Lyme will host a Zoom meeting with Robert Bransfield, MD and Pat Smith, President, Lyme Disease Association, discussing the IDSA, relationship to CDC, what are the new guidelines, how have they changed, comparison to ILADS guidelines and other topics.
Peter A. McCullough, M.D., M.P.H., Vice Chief of Internal Medicine, Baylor University Medical Center, et al. published an article in the American Journal of Medicine, August 2020: “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection.” The authors have proposed an algorithm based on age and comorbidities that allows for a large proportion to be monitored and treated at home during self-isolation with the aim of reducing the risks of hospitalization and death.
In a retrospective review on the use of Disulfiram as a repurposed drug in the treatment of Lyme and Babesiosis, most patients experienced benefits with regard to their symptoms. It was found that although patients on high dose experienced higher risk for adverse reactions than the low dose patients, they were also more likely to […]
The Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR) announced on November 30, 2020, new guidelines for prevention, diagnosis, and treatment of Lyme disease. Among the treatment recommendations, the guidelines recommend oral antibiotic therapy for most patients with Lyme disease. The recommended duration of therapy is […]
A new study published in Infectious Disease Modelling examines the relationships between incidence, prevalence, and total infection burden for Lyme borreliosis (LB) using sentinel canine and human seroprevalence data.
The researchers developed two models to estimate LB cases. One analyzed seroprevalence of Borrelia infections in human samples, applying corrections for false negative and false positive results from published test sensitivity and specificity measures.